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Abstract
Background Chronic obstructive pulmonary disease
(COPD) affects approximately 3 million people in the UK.
An 8-week pulmonary rehabilitation (PR) course is rec-
ommended under current guidelines. However, studies
show that initial benefits diminish over time.
Objective We present here an economic evaluation con-
ducted alongside a randomised controlled trial (RCT) of a
low-intensity maintenance programme over a time horizon
of 1 year delivered in UK primary and secondary care
settings.
Methods Patients with COPD who completed at least
60 % of a standard 8-week PR programme were ran-
domised to a 2-h maintenance session at 3, 6 and 9 months
(n = 73) or treatment as usual (n = 75). Outcomes were
change in Chronic Respiratory Questionnaire (CRQ) score,
EQ-5D-based QALYs, cost (price year 2014) to the UK
NHS and social services over the 12 months following
initial PR, and incremental cost-effectiveness ratios
(ICERs).
Results At 12 months, incremental cost to the NHS and
social services was -£204.04 (95 % CI -£1522 to £1114).
Incremental CRQ and QALY gains were -0.007 (-0.461
to 0.447) and ?0.015 (-0.050 to 0.079), respectively.
Based on point estimates, PR maintenance therefore
dominates treatment as usual from the perspective of the
NHS and social services in terms of cost per QALY gained.
Whether it is cost effective in terms of CRQ depends on
whether the £204 per patient could be reinvested elsewhere
to a CRQ gain of greater than 0.007. However, there is
much decision uncertainty: 95 % CIs around increments
did not exclude zero, and there is a 72.9 % (72.5 %)
probability that the ICER is below £20,000 (£30,000) per
QALY.
Conclusion Future research should explore whether more
intensive maintenance regimens offer benefit to patients at
reasonable cost.
Key Points for Decision Makers
Pulmonary rehabilitation is recommended for
chronic obstructive pulmonary disease patients; most
courses are around 2 months in length.
The effectiveness and cost effectiveness of longer
term maintenance programmes is unknown.
A 2-h maintenance session at 3, 6 and 9 months after
initial pulmonary rehabilitation programme has a
72.9 % (72.5 %) probability of yielding an
incremental cost-effectiveness ratio below £20,000
(£30,000) per QALY gained.
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1 Introduction
Chronic obstructive pulmonary disease (COPD), including
emphysema and chronic bronchitis, is a major healthcare
problem with considerable human and economic costs. It is
estimated that there are 3 million people in the UK living
with COPD, and in 2005 the annual cost of National Health
Service (NHS) treatment was estimated at over £800 mil-
lion, with a total societal cost (including lost productivity
from morbidity and premature mortality) of £2.7 billion
[1].
Therapeutic interventions comprise pharmaceutical
treatments (e.g. bronchodilators and corticosteroids) and
non-pharmaceutical treatment (including pulmonary reha-
bilitation). Pulmonary rehabilitation (PR) is recommended
under current guidelines [2] as a multicomponent pro-
gramme. A typical programme lasts 8 weeks comprising
physical exercise training and disease education with or
without nutritional, psychological and behavioural inter-
ventions. It is recommended for all patients who consider
themselves functionally disabled by COPD [usually Med-
ical Research Council (MRC) dyspnoea scale grade 3 or
above] [2, 3].
Although there is convincing evidence that PR offers
clinically relevant benefit for patients in the short to
medium term (6 months–1 year), all studies have shown
that the initial benefits diminish over time [4]. Guidelines
highlight the importance of continued exercise following
PR [5] and intensive maintenance sessions have shown
medium-term benefits [6]; however, the utility of low-in-
tensity maintenance programmes is unclear and the cost
effectiveness is not known.
Resources are finite, therefore it is essential to estimate
not only the outcomes associated with interventions, but
the costs too, in order to assist with the allocation of
healthcare resources to maximum effect, subject to the
budget. Therefore, we here present the results of cost-
effectiveness and cost-utility analyses, conducted along-
side a randomised controlled trial (RCT) of a 12-month
maintenance schedule versus treatment as usual, following
completion of a standard 2-month PR course for patients
with COPD. The analysis is conducted from the per-
spective of the UK NHS over a time horizon of 1 year
and reported in a 2012/13 price year. The health outcomes
considered are changes in Chronic Respiratory Question-
naire (CRQ) and EuroQol EQ-5D-3L survey responses.
Results are presented in terms of incremental cost-effec-
tiveness ratios (ICERs), with decision uncertainty illus-
trated using cost-effectiveness acceptability curves
(CEACs).
2 Methods
2.1 Source Study
Full details of the trial are published elsewhere [7]. In
summary, patients with COPD plus a smoking history of
more than 20 pack years and a forced expiratory volume in
1 s of\70 % predicted were eligible for entry into this
randomised controlled parallel investigator-blind study.
Participants were included if they completed at least 60 %
of the initial PR programme and as long as they had not
had a respiratory infection within 4 weeks of randomisa-
tion or other co-morbidities considered severe enough to
affect the study outcome, serious pulmonary disease other
than COPD, or history of myocardial infarction within 6
months of baseline.
A total of 237 patients received a standard PR course for
2 months. Of these, 148 completed at least 60 % of the
programme and were subsequently randomised via a
computer-generated random sequence into two groups: 73
receiving a 2-h maintenance session at 3, 6 and 9 months
after randomisation, comprising an hour of education and
an hour of structured exercise in addition to standard care.
The remaining 75 (control group) received standard care
alone. Standard care comprised encouragement to continue
exercises at the conclusion of the initial 2-month course,
and to attend a local support group for people with lung
conditions. Groups were broadly comparable at baseline
(Table 1), albeit with some differences; for example,
patients in the control group on average had a higher EQ-
5D utility (0.7 vs 0.6) [7].
This study was carried out in primary and secondary
care settings in Norfolk, England. Full ethical approval was
granted for this study by Cambridgeshire 1 Research Ethics
Committee (09/H0304/40) and the study was registered on
the clinicaltrials.gov database—identifier NCT00925171.
2.2 Outcome Measures
The primary outcome of the RCT was change in CRQ
score [8] over the 12 months following randomisation. The
secondary outcome was overall health-related quality of
life measured with the EQ-5D-3L [9]. Cost was measured
from the perspectives of both the public sector (defined as
the sum of NHS and social services costs) and society
(defined as the sum of NHS and social services costs, out-
of-pocket expenses and lost productivity). Full details of all
outcomes are reported elsewhere [7]. A 12-month time
horizon was considered a reasonable period over which to
observe any differences in primary outcome.
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Patients completed the CRQ [8], EQ-5D-3L [9, 10] and
resource use questionnaires at baseline (point of randomi-
sation), and at 3, 6, 9 and 12 months. The resource use
questionnaire is available as electronic supplementary
material. EQ-5D scores were translated to utility scores
using health state valuations relevant to the UK population
[11]. Integrating utility over time generates an estimate of
the quality-adjusted life-years (QALYs) gained over the
1-year time horizon of the study. Change in CRQ was
calculated as the difference between baseline (randomisa-
tion) and 12 months.
2.3 Resource Use and Cost
Resource use was divided into four categories: NHS,
social services, out-of-pocket expenditure and lost
productivity (Table 2). All contacts were recorded, whe-
ther or not they were considered related to a patient’s
COPD. Quantities of NHS and social services resources
(except prescribed medications) consumed were multi-
plied by unit costs extracted from standard UK sources
[12–16] (Table 3) and summed to generate total cost per
patient. Prescribed medications and doses were reported at
initiation of PR, randomisation and the final visit, 12
months following randomisation. Quantities were multi-
plied by unit costs from the British National Formulary
[17]. Lost productivity was measured in terms of wages
foregone for either the person with COPD or his/her
carer(s). The UK national median hourly wage rate [15]
was multiplied by the length of a working day (8 h), and
then multiplied by the number of days reported as taken
off work by the individual.
Table 1 Baseline characteristics
Control pre-PR Intervention pre-PR Control post-PR Intervention post-PR
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
Age (years) 75 69.3 (8.9) 73 67.3 (15.1) 75 73
Male, N (%) 75 50.0 (66.7) 73 41.0 (56.2) 75 73
CRQ dyspnoea 74 2.5 (1.2) 72 2.6 (1.0) 74 3.3 (1.3) 72 3.2 (1.1)
CRQ fatigue 74 3.4 (1.1) 72 3.2 (1.1) 74 4.0 (1.1) 72 3.9 (1.2)
CRQ emotion 74 4.4 (1.3) 72 4.2 (1.3) 74 4.9 (1.1) 72 5.2 (4.5)
CRQ mastery 74 4.8 (1.2) 72 4.2 (1.4) 74 5.0 (1.5) 72 4.6 (1.6)
ESWT (s) 69 223.5 (94.4) 67 184.4 (84.1) 69 540.7 (411.9) 67 520.9 (400.5)
ESWT (m) 70 232.0 (150.0) 65 174.8 (98.7) 70 573.5 (451.6) 65 452.9 (372.2)
BMI (kg/m2) 59 28.2 (6.0) 53 28.8 (5.7) 59 28.6 (6.3) 53 28.7 (5.8)
Body fat (%) 69 30.6 (7.1) 62 31.8 (7.4) 69 30.5 (6.7) 62 31.7 (7.2)
HADS 61 12.4 (6.9) 57 13.5 (6.9) 61 11.5 (6.9) 57 11.9 (7.0)
EQ-5D 70 0.7 (0.2) 67 0.6 (0.3) 70 0.7 (0.3) 67 0.6 (0.2)
Activity (MET mins) 60 541.8 (460.3) 49 550.1 (411.6) 60 611.1 (543.7) 49 611.7 (460.6)
Activity (VAS) 57 35.4 (22.5) 58 34.5 (16.3) 57 45.5 (20.6) 58 39.6 (21.5)
This table was adapted from Wilson et al. [7], with permission
BMI body mass index, CRQ Chronic Respiratory Questionnaire, EQ-5D EuroQol, ESWT endurance shuttle walk test, HADS hospital anxiety and
depression score, MET metabolic equivalents, PR pulmonary rehabilitation, VAS visual analogue scale
Table 2 Resource use categorisation
NHS costs Social services costs Out-of-pocket
expenditure
Lost productivity
Prescribed medications Social care Travel Patient time off work
Primary care Social services-provided equipment,
aids and devices
Other OOP Carer time off work
Secondary care (including intervention plus
NHS provided equipment, aids and devices)
Informal caring time
Other health professional
OOP out-of-pocket expenses
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Table 3 Unit costs
Cost item Unit cost Source
OP appt for COPD £137.32 Ref costs 2012–2013 [12], consultant-led outpatient attendance: not-
admitted, face-to-face attendance, follow-up. Currency code WF01A,
service code 340. Worksheet CL cell F90
OP appt for other £135.00 PSSRU 2012–2013 [13] p. 107, weighted average of all adult outpatient
procedures (follow-up face-to-face attendance)
Daycase appt for COPD £542.95 Ref costs 2012–2013 [12], day cases HRG data, worksheet DC, weighted
average of codes DZ19D-G
Daycase appt for other £697.00 PSSRU 2012–2013 [13] p. 107, weighted average of all stays
IP admission for COPD £1,543.48 Ref costs 2012–2013 [12], elective inpatient HRG data, worksheet EI, code
weighted average DZ19D-G
IP admission for other £3,283.00 PSSRU 2012–2013 [13] p. 107, weighted average of all elective IP stays
A&E attendance £115.64 PSSRU 2011–2012 [14] A&E services not leading to admitted p. 109 inflated
to 2013 prices using HCHS index (PSSRU 2012–2013 [13] p. 241)
GP surgery consultation £45.00 PSSRU 2012–2013 [13] p. 191 per surgery consultation 11.7 mins inc. direct
care staff costs and qualification costs
GP home visit £114.00 PSSRU 2012–2013 [13] p. 191, per out of surgery visit 23.4 mins inc. direct
care staff costs and qualification costs
GP phone consultation £27.00 PSSRU 2012–2013 [13] p. 191, per telecon 7.1 mins inc. direct care staff
costs and qualification costs
Nurse surgery consultation £13.43 PSSRU 2012–2013 [13] p. 188, per hour of face-to-face contact (inc.
qualifications) 9 15.5 min duration of contact
Nurse home visit £52.00 PSSRU 2012–2013 [13] p. 188, per hour of face-to-face contact (inc.
qualifications). Assumes home visit takes 1 h
Nurse phone consultation £13.43 Assumed same as surgery consultation
Health visitor surgery consultation £19.67 PSSRU 2012–2013 [13] p. 185, per hour of patient-related work 9 20/60
(length of contact - assumed 20 min)
Health visitor home visit £71.00 PSSRU 2012–2013 [13] p. 185, per home visit (inc. qualifications). Assumes
home visit takes 1 h
Health visitor phone consultation £19.67 Assumed same as surgery consultation
Physio surgery consultation £47.00 PSSRU 2012–2013 [13] p. 175, mean cost for a one-to-one contact in
physiotherapy services
Physio home visit £47.00 Assumed same as surgery consultation
Physio phone consultation £23.50 Assumed half of surgery consultation
OT surgery consultation £73.00 PSSRU 2012–2013 [13] p. 176, mean cost for a one-to-one contact in OT
services
OT home visit £73.00 Assumed same as surgery consultation
OT phone consultation £36.50 Assumed half of surgery consultation
Other AHP surgery consultation £47.00 Assumed same as physiotherapist
Other AHP home visit £47.00 Assumed same as physiotherapist
Other AHP phone consultation £23.50 Assumed same as physiotherapist
Carer home visit £24.00 PSSRU 2012–2013 [13] p. 202, per hour face-to-face weekday contact
Social worker office visit £79.00 PSSRU 2012–2013 [13] p. 198, per hour of client-related work (inc.
qualification costs)
Social worker home visit £79.00 PSSRU 2012–2013 [13] p. 198, per hour of client-related work (inc.
qualification costs)
Social worker phone call £39.50 Assumed half of home visit
Cleaner home visit £8.98 ONS Annual Survey of Hours and Earnings, 2013 [15] provisional results,
Table 13, median weekly earnings by occupation; occupation group 6,
caring, leisure and other service occupations. Assumed 37.5 h per week
Car transport to hospital £2.70 Assumed 6 miles 9 45 p per mile
Car transport to GP surgery £1.35 Assumed half distance to hospital
Public transport or taxi to
GP surgery
£11.57 Estimated from study data. Adjusted to 2013 costs using CPI [16]
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The price year of the study was 2012/13. Costs were not
discounted as the time horizon of the study was 1 year.
2.4 Analysis
Results are reported as point estimate cost and outcome
(QALYs and change in CRQ) per patient in each group,
increments and ICERs from the perspective of the NHS
and social services (i.e. public sector). Due to poor com-
pletion of questions relating to lost productivity, cost-ef-
fectiveness analysis from the perspective of society was
omitted, although we present data on out-of-pocket costs,
lost productivity and overall societal costs within the
results tables. 95 % confidence intervals around incre-
ments and CEACs were calculated using a non-parametric
bootstrap (resampling with replacement, 1000 iterations).
An analysis using least-squares regression, adjusting for
baseline covariates (cost and quality of life during the PR
period) and with missing data imputed using multiple
imputation [18] using the ‘ICE’ command in STATA,
imputing costs, utility and CRQ score at each time point,
and including baseline demographics as covariates with ten
replicated datasets is also reported (STATA do file avail-
able on request from the corresponding author). Analysis
was performed blind to treatment allocation.
3 Results
3.1 Data
Overall, patients were well matched at baseline across the
two groups, and no significant differences between any
outcome measures considered were detected at baseline
[7]. Of 148 patients randomised, data completeness was
71 %. However, due to the pattern of missingness, com-
plete data were available for only 40 patients for cost-
effectiveness analysis and 41 for cost-utility analysis. This
was due to a small number of data items missing in a large
number of observations: 30 % of observations had no
missing data and 70 % had three or fewer data items
missing. Of the 148 patients randomised, 86 % provided
responses and recorded resource use at the point of ran-
domisation and at 12 months. The use of multiple impu-
tation was therefore judged of value in this analysis.
3.2 Intervention Cost
Each PR maintenance session required two nurses (£52 per
h [13]), one physiotherapist (£34 per h [13]) and one
occupational therapist (£34 per h [13]) for 2 h. Assuming a
group size of 24 (the size of groups in the trial), the mean
cost per participant was therefore estimated at £14.33 per
session, or £43 for all three over the 12-month study
duration.
3.3 Other NHS Resource Use and Costs
There was very little difference in NHS resource use
between the groups (Table 4). Complete case analysis
(CCA) summaries of costs are presented in Table 5.
Adjusting for baseline covariates and missing data, the
intervention was observed to lead to a mean reduction in
NHS costs of £204.04 per patient over the 12-month time
horizon (Table 5 final column, Table 6). This difference
was not statistically significant (95 % CI -£1522 to 1114).
3.4 Outcomes
The 12-month maintenance programme was observed to
lead to a mean reduction in incremental CRQ of -0.007
and a gain of 0.015 QALYs (adjusted and imputed results,
Table 6). These differences were not statistically signifi-
cant (95 % CI around change in CRQ, -0.461 to 0.447 and
for QALYs, -0.050 to 0.079).
3.5 Cost Effectiveness
Point estimate results suggest the PR maintenance scheme
on average leads to lower costs but also poorer CRQ
Table 3 continued
Cost item Unit cost Source
Hourly wage £13.03 ONS Annual Survey of Hours and Earnings, 2013 [15] provisional results,
Table 3, median hourly earnings
Mean length of stay for
IP admission for COPD (days)
1.72 Ref costs 2012–2013 [12], elective inpatient HRG data, worksheet EI, code
weighted average LoS of DZ19D-G
Mean length of stay for IP
admission for other (days)
3.66 Multiplied by same proportionate difference as unit costs
A&E accident and emergency, AHP allied health professionals, Appt appointment, COPD chronic obstructive pulmonary disease, CPI Consumer
Price Index, GP general practitioner, HCHS Hospital and Community Health Service, HRG Healthcare Resource Groups, IP inpatient, ONS
Office of National Statistics, OP outpatient, OT occupational therapist, Physio physiotherapist, PSSRU Personal Social Services Research Unit
ref costs, Department of Health unit costs
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Table 4 Resource use
quantities
N (intervention,
control)
Intervention
mean (SD)
Control
mean (SD)
Primary care
GP surgery visits—COPD (30, 39) 4.20 (5.30) 3.38 (4.22)
GP surgery visits—other (30, 38) 2.87 (4.76) 1.87 (2.82)
Total (30, 38) 7.07 (8.12) 5.34 (4.73)
GP home visits—COPD (30, 39) 0.50 (1.28) 0.23 (0.84)
GP home visits—other (30, 39) 0.17 (0.75) 0.13 (0.57)
Total (30, 39) 0.67 (1.92) 0.36 (1.27)
GP phone calls—COPD (30, 39) 0.43 (1.25) 0.31 (0.73)
GP phone calls—other (30, 39) 0.30 (1.06) 0.44 (1.25)
Total (30, 39) 0.73 (1.78) 0.74 (1.48)
Nurse surgery visits—COPD (30, 39) 2.33 (4.20) 2.85 (6.41)
Nurse surgery visits—other (30, 39) 2.83 (7.35) 1.62 (4.75)
Total (30, 39) 5.17 (9.08) 4.46 (7.86)
Nurse home visits—COPD (30, 39) 0.03 (0.18) 0.15 (0.54)
Nurse home visits—other (30, 39) 1.20 (6.39) 0.13 (0.57)
Total (30, 39) 1.23 (6.38) 0.28 (0.86)
Nurse phone calls—COPD (30, 39) 0.03 (0.18) 0.10 (0.31)
Nurse phone calls—other (30, 39) 0.13 (0.73) 0.00 (0.00)
Total (30, 39) 0.17 (0.75) 0.10 (0.31)
Secondary care
OP appts—COPD (30, 39) 0.93 (1.96) 1.46 (2.02)
OP appts—other (29, 38) 1.48 (4.24) 1.95 (3.39)
Total (29, 38) 2.45 (4.51) 3.42 (4.77)
Daycase appts—COPD (30, 39) 0.03 (0.18) 0.03 (0.16)
Daycase appts—other (30, 39) 0.17 (0.46) 0.05 (0.22)
Total (30, 39) 0.20 (0.48) 0.08 (0.27)
IP admissions—COPD (30, 39) 0.30 (0.65) 0.33 (0.84)
IP admissions—other (30, 39) 0.20 (0.61) 0.10 (0.38)
Total (30, 39) 0.50 (0.97) 0.44 (0.94)
A&E attendances—COPD (30, 39) 0.03 (0.18) 0.00 (0.00)
A&E attendances—other (30, 39) 0.00 (0.00) 0.03 (0.16)
Total (30, 39) 0.03 (0.18) 0.03 (0.16)
Other health professional
Health visitor office visits (29, 38) 0.00 (0.00) 0.11 (0.51)
Health visitor home visits (29, 38) 0.00 (0.00) 0.42 (1.70)
Health visitor phone calls (29, 38) 0.00 (0.00) 0.03 (0.16)
Physiotherapist office visits (29, 38) 0.03 (0.19) 0.16 (0.82)
Physiotherapist home visits (29, 38) 0.03 (0.19) 0.05 (0.32)
Physiotherapist phone calls (29, 38) 0.00 (0.00) 0.00 (0.00)
OT office visits (28, 38) 0.00 (0.00) 0.03 (0.16)
OT home visits (28, 38) 0.18 (0.67) 0.08 (0.27)
OT phone calls (28, 38) 0.11 (0.57) 0.00 (0.00)
Other HP office visits (26, 38) 1.04 (4.69) 0.32 (1.09)
Other HP home visits (26, 38) 0.08 (0.27) 0.82 (3.34)
Other HP phone calls (26, 38) 0.08 (0.27) 0.18 (1.14)
Other phone calls (30, 39) 0.00 (0.00) 0.13 (0.66)
Social services
Social services office visit (30, 39) 0.00 (0.00) 0.00 (0.00)
Social services home visit (30, 39) 0.00 (0.00) 0.08 (0.48)
Social services phone call (30, 39) 0.00 (0.00) 0.00 (0.00)
A&E accident and emergency, COPD contact due to chronic obstructive pulmonary disease, GP General Prac-
titioner, HP health professional, IP Inpatient, OP Outpatient, OT Occupational Therapist, SD standard deviation
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outcomes (Table 6). Therefore, the financial gain for every
foregone point deterioration in CRQ is £29,295. On aver-
age, we observed a positive incremental QALY gain,
meaning the intervention was dominant (less costly and
more effective). Considering decision uncertainty, a scat-
terplot of cost–QALY pairs (Fig. 1) suggests that PR
maintenance is approximately equally likely to be cost
saving or cost incurring (there is a more or less equal
spread of points north and south of the x-axis), but with a
slightly higher probability of generating a positive incre-
mental QALY gain (more of the points are to the east of the
y-axis). These observations are reflected in the confidence
intervals around incremental cost and outcomes (Table 6,
adjusted analyses) and the CEAC (Fig. 2), suggesting a
72.88 % probability of cost effectiveness at a threshold of
£20,000 per QALY, declining slightly to 72.52 % at a
£30,000 threshold.
4 Discussion
4.1 Interpretation of Results
A strict decision-theoretic interpretation of the results
(where decisions are based on point estimates alone) would
be that, on average, our results suggest PR maintenance is
less expensive, but yields worse outcomes on one mea-
surement scale (CRQ) but better outcomes on another
(QALYs). One approach to resolve this contradiction is to
define a preferred analysis; as QALYs are the more generic
health outcome measure (and also allow broad comparison
across disease areas), this may be the more useful analysis.
Based on our findings, one would conclude that mainte-
nance of PR ‘dominates’ control as it is both less expensive
and more effective. An alternative interpretation based
strictly on the rules of statistical inference would argue that
there is no statistically significant difference in either cost
or outcomes (conventionally defined as a 95 % confidence
interval that excludes zero), and therefore it is not possible
to conclude that one course of action is more cost effective
than another.
However, a compromise between these two interpreta-
tions would observe that, whilst neither incremental costs
nor outcomes were statistically significant at a 95 % con-
fidence level, incremental QALY gain is more likely than
not to be positive, whilst there is equal probability of a cost
increase or decrease (columns adjusted analyses, incre-
mental costs and outcomes, Table 6). Formally quantifying
this into uncertainty in cost effectiveness, there is a
72.52 % probability that PR maintenance is cost effective
at a willingness-to-pay threshold of £30,000 per QALY
(final column, Table 6). Whether this is sufficient certainty
to recommend adoption of maintenance therapy depends
on the attitude to risk of the decision maker (assuming a
£30,000 threshold is considered the upper limit of cost
effectiveness).
The finding of no significant difference in outcome at
12 months was disappointing. Whilst we observed a sig-
nificant improvement in CRQ scores amongst completers
over the initial 2-month programme [7], this improvement
was not maintained in either randomisation group. A pos-
sible explanation for this is that the maintenance regimen
was either not of sufficient intensity or was not commenced
early enough to affect a significant or clinically relevant
change. In addition, the adherence to our planned mainte-
nance regimen was poor (52 % of individuals completing
all planned sessions) although the clinical efficacy in this
group of individuals (the intention-to-treat analysis) was
Table 5 Summary costs
N (intervention,
control)
Intervention mean
(SD)
Control mean
(SD)
Unadjusted increment
mean (SE)
Adjusted increment
mean (SE)
Cost of intervention (73, 75) 43.00 (0.00) 0.00 (0.00) 43.00 (0.00)
Drug costs (65, 68) 973.13 (1503.57) 717.97 (707.17) 255.15 (202.31)
Primary care (30, 38) 549.56 (706.45) 380.61 (328.55) 168.95 (129.19)
Secondary care (29, 38) 1637.88 (2558.23) 1308.61 (2147.43) 329.27 (575.32)
Other HP (26, 36) 40.56 (144.77) 108.05 (313.77) -67.49 (66.20)
Total NHS costs (22, 29) 3355.49 (4126.28) 2600.03 (2679.60) 755.47 (954.61) -204.04 (672.52)
Social services (30, 39) 0.00 (0.00) 6.08 (37.95) -6.08 (6.94)
Patient OOP costs (17, 23) 75.36 (149.09) 27.65 (29.99) 47.71 (31.79)
Indirect costs (8, 10) 792.39 (1268.26) 979.86 (1181.28) -187.47 (578.74)
Total societal costs (7, 7) 3666.04 (3246.03) 1512.01 (2277.64) 2154.02 (1498.78) Not available
Data reported are complete case analysis (means and ‘unadjusted increment’), and adjusted for baseline characteristics and missing data imputed
(‘adjusted increment’ column)
HP health professional, OOP out of pocket, SD standard deviation, SE standard error of the mean
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similar to the group as a whole (per protocol analysis) [7].
It is possible that a more intensive regimen may be more
effective, but at increased cost. However, estimating this is
beyond the scope of this study. It should be noted that only
62 % of eligible patients enrolled to the initial PR course
were able to complete at least 60 % of it (and thus meet the
entry criteria to this study). We have no reason to suspect
this may be any different from the completion rate
observed in practice, thus our results should be generalis-
able. However, this does raise questions as to whether it
may be more efficient to encourage completion of existing
courses, rather than exploring maintenance regimens.
Again, exploration of this is beyond the scope of this study.
4.2 Comparison with Other Studies
At the time of writing, we were unable to identify any
previous studies of the cost effectiveness of group-based
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approaches to maintenance of PR on conclusion of the
initial scheme [3]. The most similar study was an eval-
uation of a low intensity (once weekly) PR course over a
26-week time horizon in Germany. This study suggested
evidence of a clinically beneficial effect over this time
period, at a staff cost of no more than €625 (price year
unknown) [19], although other healthcare costs (e.g. other
health service contacts) were not measured. Although not
entirely comparable as CRQ was not used as an outcome
measure, another study from the Netherlands investigated
cost effectiveness and cost utility of a community-based
20-month management scheme following 4 months of
intensive PR [20]. During the maintenance period of
20 months, patients made monthly visits to a physio-
therapist, four visits to a nutritionist, various visits to a
respiratory nurse, and up to six physical training sessions.
The ICER was estimated to be €32,425 (price year 2007)
per QALY, and the probability of cost effectiveness at
willingness to pay of €20,000 per QALY was estimated
at 33 % (67 % at €50,000). From this, the authors con-
cluded that the intervention was moderately cost
effective.
There are, however, a number of studies of the cost
effectiveness of variants of the initial PR programme in
patients with COPD.
In 2001, Griffiths et al. [21] estimated that at 1 year after
a 6-week outpatient PR programme in Wales, UK, incre-
mental costs per patient (NHS costs plus patient out-of-
pocket expenditure on travel) in the intervention group
were lower than in the control (standard care without PR),
but outcomes were also superior, with a high probability of
cost effectiveness irrespective of the threshold. This study
provided the major economic evidence supporting NICE’s
2010 (and current) recommendation in favour of provision
of PR ‘for all who need it’ [2].
In contrast, a more recent study by Gillespie et al. [22]
reported the cost effectiveness in an Irish setting of an
8-week structured PR programme for COPD patients
similar to that given to all patients in our trial, with a
follow-up at 22 weeks. Costs included those associated
with delivering the intervention, other primary and sec-
ondary healthcare and social services contacts and pre-
scribed medications, as well as private costs to patients
(time and travel expenses). The authors estimated that the
intervention yielded an incremental cost of €472,000
(£369,000) (price year 2009) per QALY gained, consid-
erably above any ‘reasonable’ threshold.
Other studies have compared alternative means to deli-
ver PR. An RCT-based study of a 6-week programme of
hospital versus community-based PR, with and without
telephone follow-up in patients with COPD, evaluated
costs and outcomes at 18 months [23]. The authors found a
50 % probability of cost effectiveness of hospital versus
community PR at a £30,000 per QALY threshold. Tele-
phone follow-up appeared to improve outcomes at rea-
sonable cost in the community-based group but not the
hospital group.
4.3 Strengths and Weaknesses
This analysis is based on a well conducted RCT with a
relatively long (12-month) time horizon, adhering to
recognised standards for the conduct and reporting of
economic evaluations [24].
A potential weakness of the study was the capture of
data from questionnaire rather than source databases such
as GP, secondary care or social care records. Collecting
data in this way allows the data to be assembled in a
consistent form reducing the analytic burden somewhat,
however risks introducing recall bias. Evidence suggests
that patient recall for salient events such as secondary care
is relatively reliable, but recall for primary care contacts is
less so [25], but still within acceptable bounds when
respondents are only asked to recall frequency of contact
and not duration [26] (as was the case in this study). In our
study, secondary care was a bigger cost driver than primary
care, thus limiting the impact of any recall bias. There is
also no reason to believe that recall bias may be greater in
one arm than in the other.
Of note is the seeming contradiction between the CRQ
and QALY results, and furthermore the difference in the
results between the ‘raw’ CCA, and the imputed analysis,
adjusted for baseline characteristics. Given the wide con-
fidence intervals, this is highly likely a chance finding.
However, it is also plausible that the EQ-5D instrument is
insensitive in this population, or conversely that the EQ-5D
picks up broader improvements in quality of life not cap-
tured by the CRQ. It should be noted that the CCA will be
subject to greater sampling uncertainty due to exclusion of
observations for which there are incomplete responses. We
employed a very strict definition of complete case, such
that patients with any cost or outcome data missing at any
time point were excluded. As a result, this analysis
excludes a large quantity of relevant data. It should also be
noted that QALYs are particularly sensitive to baseline
imbalances in utility [27]. A priori, therefore, the adjusted,
imputed analysis represents a preferable interpretation of
the data, and as explained above, QALYs could be con-
sidered a preferred outcome measure over CRQ. However,
for ease of computation, we used a simple ordinary least
squares (OLS) model to adjust for baseline characteristics.
The difference in the results between the CCA and imputed
analyses suggests caution should be expressed in
interpretation.
A major limitation of this study was the poor quality and
quantity of data relating to lost productivity; these data
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were missing in most cases. A reason for this could be
respondent fatigue: these questions appeared at the end of a
lengthy battery of measures. Future methodological work
should focus on improving phrasing of the required ques-
tions whilst minimising burden on respondents.
The time horizon of the study was 1 year. The ideal time
horizon for an economic evaluation is sufficient to observe
any changes in incremental cost or outcomes. We were
limited to a within-trial study in this case. If there is expected
to be a difference in incremental cost or outcomes beyond
this time horizon, then decisionmodellingmay be of value to
project observed costs and outcomes to the future.
5 Conclusion
Whilst, on average, our results suggest PR maintenance is
cost effective from the perspective of the NHS, this is
based on there being a very small increase in QALYs
gained but no difference in NHS costs. The wide confi-
dence intervals around incremental costs and outcomes are
reflected in our finding that there is a 73 % probability that
the ICER is below £30,000 per QALY gained.
Future research should focus on exploring whether more
intense maintenance regimens are able to offer a benefit to
patients at reasonable cost.
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